Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
04. Februar 2016 10:22 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
Xeris Pharmaceuticals Announces $41 Million Series C Financing
07. Januar 2016 10:24 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance a Stable, Non-Aqueous Diazepam, Subcutaneous Injection for Treatment of Acute Repetitive Seizures in Patients with Epilepsy
01. Oktober 2015 10:15 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Oct. 01, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments, was...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease
14. April 2015 14:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for...
Xeris Pharmaceuticals Completes $17.9M Series B Round and Appoints Phillip Johnson as Chief Financial Officer
07. Januar 2015 14:39 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a clinical-stage, specialty
biopharmaceutical company developing novel, non-aqueous
formulations of injectable drugs,...
FDA and EMA Grant Orphan Designation to Xeris Pharmaceuticals' Soluble Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Patients
12. November 2014 10:57 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"),a clinical stage,
specialty biopharmaceutical company developing novel, non-aqueous
formulations of injectable...
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon for the Treatment of Mild-to-Moderate Hypoglycemia
05. Juni 2014 11:19 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, June 5, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage,
specialty biopharmaceutical company developing novel, non-aqueous
formulations of injectable...
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps
24. April 2014 12:19 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, April 24, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage,
specialty biopharmaceutical company developing novel, non-aqueous
formulations of injectable...
Xeris Pharmaceuticals Receives U.S. Patent for its Novel, Stable Non-Aqueous Glucagon Formulations
16. April 2014 10:42 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, April 16, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is
has been granted U.S. Patent No. 8,697,644, "Stable Formulations
for Parenteral...
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation
17. Oktober 2013 12:00 ET
|
Xeris Pharmaceuticals, Inc.
AUSTIN, Texas, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage,
specialty biopharmaceutical company developing novel non-aqueous
formulations of injectable...